logo-loader

Dyadic International posts higher revenue from R&D, new sublicensing collaborations

Published: 14:45 10 May 2019 EDT

Dyadic International Inc (NASDAQ:DYAI) Chief Accounting Officer Ping Rawson says the Florida-based biotech reported a 119% increase in first-quarter research and development revenue compared to the same period a year ago.

Chief Scientific Officer Ronen Tchelet explained the value of its recently formed, exciting sub-licensing agreements with both Alphazyme and Serum Institute of India.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 20 minutes ago